{"id":162960,"date":"2022-08-13T01:57:11","date_gmt":"2022-08-13T05:57:11","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/checkpoint-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-highlights\/"},"modified":"2024-08-18T11:45:12","modified_gmt":"2024-08-18T15:45:12","slug":"checkpoint-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-highlights","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/checkpoint-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-highlights.php","title":{"rendered":"Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights"},"content":{"rendered":"<p><![CDATA[Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022]]><\/p>\n<p>Continue reading here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/08\/12\/2497549\/0\/en\/Checkpoint-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Corporate-Highlights.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights\">Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Continue reading here: Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/checkpoint-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-highlights.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-162960","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/162960"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=162960"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/162960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=162960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=162960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=162960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}